Jamma Li

Clinical posts from members and guests of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) from various international medical and scientific conferences on HIV, AIDS, viral hepatitis, and sexual health.

Still very early data presented on maturation inhibitor BMS-955176

Posted by on in New ARV Treatment, clinical trials emerging therapy
  • Font size: Larger Smaller
  • Hits: 757
  • Print
Data from the BMS-955176 Phase IIa proof of concept study was presented.
 
Short 10 day monotherapy were conducted for HIV-1 subtype B and C in treatment naive or experienced subjects to demonstrate virologic suppression. 1.64 log was achieved at doses above 40mg for B and 1.35 log for C.
 
The study also concluded comparable virologic control over 28 days with standard of care TDF+FTC+ATV/R with a 2.23 log fall in viral load at Day 28.
 
Still too early to tell I think.
Tagged in: EACS2015
  • No comments made yet. Be the first to submit a comment

Leave your comment

Guest
Guest Thursday, 23 November 2017

RT @hepqld: Curing #hepatitis C is easy, and no longer needs a specialist to prescribe treatment. Community doctors play a pivotal role in…

ASHM ASHM